Skip to main content
OpenTrials

Clinical trial condition

Glomerulonephritis, IGA

Explore clinical trials studying Glomerulonephritis, IGA. Study availability and eligibility vary by location and protocol.

203 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Glomerulonephritis, IGA trial results

Enrolling by invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Clinical Research Site #336 Birmingham, Alabama, United States
  • Clinical Research Site #325 Los Angeles, California, United States
  • Clinical Research Site #370 Palo Alto, California, United States
  • Clinical Research Site #330 Denver, Colorado, United States
View all 158 locations
View Trial Details
Active, not recruiting

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

NCT06712407

Conditions
Autoimmune Diseases, Chronic Disease, Disease Attributes, +16 more
Locations
  • Univ of Alabama/Birmingham Birmingham, Alabama, United States
  • Arizona Kidney Disease & Hypertension Centers (AKDHC) Glendale, Arizona, United States
  • The Medical Research Group, Inc. Fresno, California, United States
  • UCI Health-UCI Medical Center Orange, California, United States
View all 38 locations
View Trial Details
Active, not recruiting

A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases

NCT06786338

Conditions
Autoimmune Diseases, C3 Glomerulopathy, Female Urogenital Diseases, +11 more
Locations
  • Peking University First Hospital Beijing, China
  • Peking University People's Hospital Beijing, China
  • The Third Xiangya Hospital of Central South University Changsha, China
  • Sichuan Provincial People's Hospital Chengdu, China
View Trial Details
Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • UAB Nephrology Research Clinic Birmingham, Alabama, United States
  • Kidney Disease Medical Group Inc-1505 Wilson Ter Glendale, California, United States
  • Academic Medical Research Institute - Los Angeles Los Angeles, California, United States
  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica Los Angeles, California, United States
View all 178 locations
View Trial Details
Active, not recruiting

Serum and Urinary sCD163 in IgA Nephropathy

NCT07754019

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
Locations
  • Bezmialem Vakif University Health Application and Research Center Istanbul, Turkey (Türkiye)
View Trial Details
Active, not recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462

Conditions
Autoimmune Diseases, Chronic Disease, Disease Attributes, +15 more
Locations
  • AZ Kidney Dise and Hypertension Ctr Glendale, Arizona, United States
  • Kaiser Permanente San Diego, California, United States
  • North America Research Institute San Dimas, California, United States
  • University of Colorado Anschutz Aurora, Colorado, United States
View all 155 locations
View Trial Details
Active, not recruiting

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • University of Alabama at Birmingham - Site #336 Birmingham, Alabama, United States
  • Mayo Clinic Arizona - Site #363 Phoenix, Arizona, United States
  • University of Arkansas for Medical Sciences - Site #353 Little Rock, Arkansas, United States
  • Amicis Research Center - Site #341 Granada Hills, California, United States
View all 308 locations
View Trial Details

Related conditions